

AD _____

Award Number: W81XWH-04-1-0314

TITLE: Prostate Cancer Aggressiveness Genes in Hereditary
Prostate Cancer

PRINCIPAL INVESTIGATOR: Kathleen A. Cooney, M.D.

CONTRACTING ORGANIZATION: The University of Michigan Medical School
Ann Arbor, Michigan 48109-0602

REPORT DATE: March 2005

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20060503129

REPORT DOCUMENTATION PAGE

*Form Approved
OMB No. 074-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)			2. REPORT DATE March 2005	3. REPORT TYPE AND DATES COVERED Annual (1 Mar 2004 - 28 Feb 2005)
4. TITLE AND SUBTITLE Prostate Cancer Aggressiveness Genes in Hereditary Prostate Cancer			5. FUNDING NUMBERS W81XWH-04-1-0314	
6. AUTHOR(S) Kathleen A. Cooney, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Michigan Medical School Ann Arbor, Michigan 48109-0602			8. PERFORMING ORGANIZATION REPORT NUMBER	
E-Mail: kcooney@umich.edu				
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) No abstract provided.				
14. SUBJECT TERMS No subject terms provided.				15. NUMBER OF PAGES 5
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusions.....	5

INTRODUCTION: The *EZH2* transcriptional regulator, recently shown by to be overexpressed in prostate cancer specimens that are more likely to recur, maps to 7q35 and represents a candidate gene for inherited prostate cancer susceptibility. This statement is based on the identification of prostate cancer linkage to distal 7q markers in a recently completed genome-wide scan using hereditary prostate cancer families from the University of Michigan Prostate Cancer Genetics Project (PCGP). Relatively little is known about the molecular basis of *EZH2* function or its DNA specificity. The major hypothesis of this proposal is that germline mutations in the *EZH2* gene will predispose to more clinically aggressive forms of prostate cancer and the characterization of these mutations will provide more information about the function of the *EZH2* molecule in prostate cancer and metastasis. To address this hypothesis, the following two specific aims were proposed: 1) to identify germline mutations in *EZH2* that predispose to aggressive prostate cancer in prostate cancer families, and 2) to characterize the functional consequences of *EZH2* mutations specifically focusing on the role of *EZH2* in transcriptional regulation.

BODY: To address Specific Aim 1, we have revised our current IRBMED approved research project to add this DOD-funded research project. The revised proposal is under review by our University of Michigan IRB. We expect that this will be approved by April 2005. In the interim, we have designed sequencing primers to span all of the *EZH2* coding regions. The primers have been tested on control DNA samples and conditions for amplification have been standardized.

To address Specific Aim 2, we have modified a molecular biological technique first developed in yeast, known as the TAP (tandem affinity purification) system, which has allowed us to express a tagged form of *EZH2* in human cells at physiological concentrations, and subsequently to purify *EZH2*-associated proteins from cells. We have identified several *EZH2*-binding proteins by mass spectrometry, and our lead candidate is a recently described factor designated REA (repressor of estrogen activity). We have isolated full-length cDNA clones encoding REA, and generated a range of mammalian expression vectors, both with and without epitope tags. Through coprecipitation experiments, we have confirmed the validity of the interaction, and our studies have now moved to the next phase, namely the functional characterization of the two proteins to determine the physiological consequences of the interaction.

REA has been shown to bind directly to the estrogen receptor (ER), and can function to suppress ER-mediated activity. We therefore are taking several approaches to examine the functional consequences of the *EZH2*-REA interaction. Firstly, we have established a system described recently by the laboratory of Danny Reinberg, in which the transcription suppressing activity of *EZH2* is examined through the use of a Gal4-*EZH2* chimera. By monitoring the expression of a Gal4-dependent luciferase reporter construct, we are in the process of examining the effects of either ectopic expression, or removal by RNA interference, of REA on *EZH2* activity.

We have obtained several monoclonal antibodies specific to REA, and we are taking an immunohistochemical approach to examine a panel of histological samples to determine whether REA expression is altered in prostate cancer.

Finally, we are testing the reciprocal possibility, namely that *EZH2* is involved in REA function, and to this end we have established a similar luciferase-based reporter

system to that described above to examine the effect of *EZH2* on estrogen receptor-mediated transcription. The hypothesis being tested is that REA-mediated inhibition of ER activity may be modulated by, or even mediated by *EZH2*.

KEY RESEARCH ACCOMPLISHMENTS:

- | | |
|----------------|--|
| Specific Aim 1 | Completion and approval of IRB protocols.
Design and validation of exon-specific primers |
| Specific Aim 2 | Establishment of <i>EZH2</i> -TAP system
Purification and identification of <i>EZH2</i> -associated proteins
Validation of REA as a physiologically relevant <i>EZH2</i> -associated protein
Characterization of REA-specific antibodies for Immunohistochemistry
Establishment of reporter systems to analyze <i>EZH2</i> and REA Activity
Design and validation of small interfering RNAs (siRNAs) for REA and XIAP |

REPORTABLE OUTCOMES: None to date.

CONCLUSIONS: We are now very excited about the ability to proceed with Specific Aim 1, having, we believe, updated and amended the IRB protocols in a manner which is satisfactory to the DOD. Specific Aim 2 has also seen significant progress, with the identification and validation of REA as a previously undescribed *EZH2*-interacting protein. In summary, we feel that we are well underway in the successful undertaking of our aims.